Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3
World
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3
World
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Group",
"id" : "588218",
"meta" : {
"versionId" : "7",
"lastUpdated" : "2026-08-15T16:32:10.010Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/pico-specification"
]
},
"language" : "en",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Group 588218</b></p><a name=\"588218\"> </a><a name=\"hc588218\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 7; Last updated: 2026-08-15 16:32:10+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-pico-specification.html\">PICOSpecification</a></p></div><p><b>Artifact Author</b>: Khalid Shahin: </p><p><b>ArtifactRecorder</b>: Khalid Shahin: </p><p><b>CiteAs</b>: </p><div><p>PICO: Intensive versus standard blood-pressure control for major adverse cardiovascular events in adults at increased cardiovascular risk [Database Entry: FHIR Group Resource]. Contributors: Khalid Shahin [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 588218. Revised 2026-08-15. Available at: https://fevir.net/resources/Group/588218. Computable resource at: https://fevir.net/resources/Group/588218#json.</p>\n</div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"https://fevir.net/resources/Group/588218\">https://fevir.net/resources/Group/588218</a></p><p><b>identifier</b>: FEvIR Object Identifier/588218, <code>http://example.org/fhir/sid/pico-register</code>/PICO-2026-0142\u00a0(use:\u00a0official,\u00a0)</p><p><b>title</b>: PICO: Intensive versus standard blood-pressure control for major adverse cardiovascular events in adults at increased cardiovascular risk</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href=\"mailto:support@computablepublishing.com\">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><p><b>copyright</b>: </p><div><p>Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).</p>\n</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: All of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 population}\">Population</span></p><p><b>value</b>: <span title=\"Codes:{http://snomed.info/sct 38341003}\">Hypertension with systolic blood pressure 130-180 mmHg and at least one additional cardiovascular risk factor</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Adults with a measured systolic blood pressure between 130 and 180 mmHg inclusive, together with at least one of: clinical or subclinical cardiovascular disease, chronic kidney disease with eGFR 20-59 mL/min/1.73 m2, a 10-year Framingham risk score of 15 percent or greater, or age 75 years or older.</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/usage-context-type age}\">Age Range</span></p><p><b>value</b>: 50-? years</p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Aged 50 years or older at the time of eligibility assessment. No upper age limit is applied.</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 intervention}\">Intervention</span></p><p><b>value</b>: <span title=\"Codes:\">Intensive blood-pressure control: antihypertensive therapy titrated to a systolic target below 120 mmHg</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Any antihypertensive regimen titrated at monthly intervals to achieve and maintain a systolic blood pressure below 120 mmHg. The specific agents used are not constrained by this question.</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 comparator}\">Comparator</span></p><p><b>value</b>: <span title=\"Codes:\">Standard blood-pressure control: antihypertensive therapy titrated to a systolic target below 140 mmHg</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Any antihypertensive regimen titrated to achieve and maintain a systolic blood pressure below 140 mmHg, reflecting the guideline-recommended target in force at the time the question was formulated.</p>\n</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 outcome-measure}\">Outcome Measure</span></p><p><b>value</b>: <span title=\"Codes:\">Major adverse cardiovascular events: composite of myocardial infarction, other acute coronary syndrome, stroke, acute decompensated heart failure, or death from cardiovascular causes</span></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>Time to first occurrence of any component of the composite, adjudicated by a committee unaware of treatment assignment. Individual components are reported as separate outcome measures in the evidence report.</p>\n</div><h3>RelativeTimes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Offset[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>No display for Duration (value: 5; unit: years; system: http://unitsofmeasure.org; code: a)</td></tr></table></blockquote></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail" : {
"name" : "Khalid Shahin"
}
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-recorder",
"valueContactDetail" : {
"name" : "Khalid Shahin"
}
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as",
"valueMarkdown" : "PICO: Intensive versus standard blood-pressure control for major adverse cardiovascular events in adults at increased cardiovascular risk [Database Entry: FHIR Group Resource]. Contributors: Khalid Shahin [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 588218. Revised 2026-08-15. Available at: https://fevir.net/resources/Group/588218. Computable resource at: https://fevir.net/resources/Group/588218#json."
},
{
"url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code" : "active",
"display" : "Active"
}
]
}
}
],
"url" : "https://fevir.net/resources/Group/588218",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "https://fevir.net/FOI",
"value" : "588218",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"use" : "official",
"system" : "http://example.org/fhir/sid/pico-register",
"value" : "PICO-2026-0142"
}
],
"title" : "PICO: Intensive versus standard blood-pressure control for major adverse cardiovascular events in adults at increased cardiovascular risk",
"status" : "active",
"publisher" : "Computable Publishing LLC",
"contact" : [
{
"telecom" : [
{
"system" : "email",
"value" : "support@computablepublishing.com"
}
]
}
],
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"copyright" : "Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).",
"membership" : "conceptual",
"combinationMethod" : "all-of",
"characteristic" : [
{
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "population",
"display" : "Population"
}
]
},
"valueCodeableConcept" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "38341003",
"display" : "Hypertensive disorder, systemic arterial"
}
],
"text" : "Hypertension with systolic blood pressure 130-180 mmHg and at least one additional cardiovascular risk factor"
},
"exclude" : false,
"description" : "Adults with a measured systolic blood pressure between 130 and 180 mmHg inclusive, together with at least one of: clinical or subclinical cardiovascular disease, chronic kidney disease with eGFR 20-59 mL/min/1.73 m2, a 10-year Framingham risk score of 15 percent or greater, or age 75 years or older."
},
{
"code" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/usage-context-type",
"code" : "age",
"display" : "Age Range"
}
]
},
"valueRange" : {
"low" : {
"value" : 50,
"unit" : "years",
"system" : "http://unitsofmeasure.org",
"code" : "a"
}
},
"exclude" : false,
"description" : "Aged 50 years or older at the time of eligibility assessment. No upper age limit is applied."
},
{
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "intervention",
"display" : "Intervention"
}
]
},
"valueCodeableConcept" : {
"text" : "Intensive blood-pressure control: antihypertensive therapy titrated to a systolic target below 120 mmHg"
},
"exclude" : false,
"description" : "Any antihypertensive regimen titrated at monthly intervals to achieve and maintain a systolic blood pressure below 120 mmHg. The specific agents used are not constrained by this question."
},
{
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "comparator",
"display" : "Comparator"
}
]
},
"valueCodeableConcept" : {
"text" : "Standard blood-pressure control: antihypertensive therapy titrated to a systolic target below 140 mmHg"
},
"exclude" : false,
"description" : "Any antihypertensive regimen titrated to achieve and maintain a systolic blood pressure below 140 mmHg, reflecting the guideline-recommended target in force at the time the question was formulated."
},
{
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"valueCodeableConcept" : {
"text" : "Major adverse cardiovascular events: composite of myocardial infarction, other acute coronary syndrome, stroke, acute decompensated heart failure, or death from cardiovascular causes"
},
"exclude" : false,
"description" : "Time to first occurrence of any component of the composite, adjudicated by a committee unaware of treatment assignment. Individual components are reported as separate outcome measures in the evidence report.",
"relativeTime" : [
{
"offsetDuration" : {
"value" : 5,
"unit" : "years",
"system" : "http://unitsofmeasure.org",
"code" : "a"
}
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support.
Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-ballot5.
Generated
2026-08-17
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change